Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CS060380 Phase I in Healthy and Elevated LDL-C Subjects
NCT06573528Phase 1Completed
- Sponsor
- Cascade Pharmaceuticals
- Start
- Sep 2024
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of thybetaxor in metabolic dysfunction-associated steatohepatitis (MASH) and hypercholesterolemia (13 arms), sponsored by Cascade Pharmaceuticals. Primary endpoint: Adverse Events. Started Sep 2024; status: completed.
02
Drugs
thybetaxor
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)hypercholesterolemia
Beyond the preview
Go deeper on NCT06573528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06573528.